A Phase 3 trial investigating screening methods for Colorectal Cancer reached primary completion on 2026-03-05, enrolling 4952 participants. The study, titled "Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer," aimed to compare the effectiveness of colonoscopy against the fecal occult blood test (FOBT).
Background
Colorectal cancer remains a significant public health concern, with early detection being crucial for improved treatment outcomes. Screening tests play a vital role in identifying tumor cells or precancerous lesions at an early stage, often before symptoms appear. Common screening methods include colonoscopy, which allows for direct visualization and biopsy of the colon, and the fecal occult blood test, which detects hidden blood in stool that may indicate the presence of polyps or cancer. Understanding the comparative efficacy of these screening approaches is essential for guiding clinical practice and public health recommendations.
Trial design
This randomized Phase 3 trial, which has now completed its primary data collection, enrolled 4952 healthy participants to be screened for Colorectal Cancer. The study's purpose was to evaluate how well colonoscopy works when compared to the fecal occult blood test in screening for colorectal cancer. Participants were randomized to receive either colonoscopy or a fecal occult blood test as their primary screening method.
Source
Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The event, a primary completion, was recorded on 2026-03-05 for study NCT00102011, titled "Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer," on clinicaltrials.gov.